In the case of Association for Molecular Pathology v. Myriad Genetics, Inc. theĀ U.S. Supreme Court unanimously ruled that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but synthetic complementary DNA (“cDNA”) is patent eligible because it is not naturally occurring.

The distinction is a critical one, as it opens the door for broad application certain genetic testing, while preserving important patent rights for the biotechnology industry.

Jorge Goldstein, Ph.D, of Sterne Kessler Goldstein & Fox PLLC, who is one of the leading pioneers in biotechnology patent law, discusses both legal and scientific ramifications of the case in this podcast interview.

You can listen to the episode now by clicking the play button on the built-in player below, or download and listen later by right-clicking here.

Please follow and like us:
Pin Share